Do central nervous system lesions caused by Burkholderia (melioidosis) typically resolve on imaging after the intensive‑phase intravenous therapy?

CNS Melioidosis Lesions on Imaging After Intensive Phase

Yes—but not reliably: CNS melioidosis lesions often improve radiologically after adequate intensive IV therapy, but complete resolution is variable and may lag behind clinical recovery; persistent residual changes are common and warrant prolonged therapy and follow‑up. 1, 2, 3

• Core recommendation (mortality/morbidity/QOL prioritized)

  • Use a prolonged intensive phase for neurologic melioidosis (ceftazidime or meropenem/imipenem), then mandatory eradication therapy to prevent relapse and disability. Expect radiologic improvement; do not require complete resolution before stepping down if the patient is clinically improving and microbiology is controlled. 1

• Guideline‑anchored therapy and monitoring

  • Intensive phase:
    • Ceftazidime or meropenem/imipenem for at least 14 days; extend to 4–8 weeks or longer in neurologic melioidosis/CNS abscess or critical illness. Add TMP‑SMX if CNS involved. This approach reduces mortality and relapse. 1
  • Eradication phase:
    • TMP‑SMX for 3–6 months (preferred) to prevent recrudescence; alternatives only if TMP‑SMX intolerant. This improves long‑term outcomes and QOL by preventing relapse. 1
  • Imaging expectations:
    • MRI/CT typically shows interval improvement during/after intensive phase; complete radiologic clearance may take weeks–months and T2/FLAIR residuals may persist without active infection. Base decisions primarily on clinical response and microbiologic control. 1, 2, 3

• Evidence snapshots (highest‑quality, most recent, most relevant)

  • Guideline table explicitly recommends longer intensive therapy and adding TMP‑SMX for CNS involvement; prolonged courses for “neurologic melioidosis.” Imaging improvement is expected; complete resolution not required before de‑escalation if stable. 1
  • Case data show radiologic resolution/improvement after intensive therapy ± surgery (e.g., subdural collection improved by 7 weeks on MRI after 8 weeks meropenem+TMP‑SMX; complete clinical recovery after 8 weeks IV meropenem with prolonged TMP‑SMX). These support expecting improvement but variable timelines to full resolution. 2, 3
  • Additional recent cases describe interval radiologic resolution after drainage plus carbapenem therapy, reinforcing that source control + adequate duration are key for radiologic clearance and outcomes. 4

• Practical algorithm

  • If CNS melioidosis suspected/confirmed:
    • Start meropenem or ceftazidime immediately; add TMP‑SMX for CNS disease. Plan 4–8+ weeks IV if abscess/empyema/brainstem/spinal disease. 1
    • Obtain early neurosurgical input for drainable collections; source control accelerates radiologic and clinical resolution. 4, 3
    • Re‑image at 2–4 weeks to document trend; expect partial regression. Do not equate persistent T2/FLAIR changes with failure if patient is improving. 1
    • Transition to TMP‑SMX eradication for 3–6 months once clinically stable and afebrile with down‑trending markers; continue periodic imaging until clear downward trajectory or stability without enhancement. 1
    • If radiology worsens or patient deteriorates, escalate: reassess for undrained foci, extend/intensify IV therapy, consider combination and re‑drain. 1

• Common pitfalls and how to avoid them

  • Stopping IV therapy too early in CNS disease; use extended courses (4–8+ weeks) to reduce relapse and disability. 1
  • Skipping eradication therapy—major driver of relapse and worse QOL; give full TMP‑SMX course. 1
  • Over‑interpreting residual MRI abnormalities as active infection; correlate with symptoms and enhancement patterns. 1
  • Delayed or omitted source control for empyema/abscess; timely drainage improves outcomes and speeds radiologic resolution. 4, 3